TAM
REGN icon

Taurus Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Taurus Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.6M Sell
16,711
-414
-2% -$285K 1.07% 35
2024
Q4 		$12.2M Buy
17,125
+1,130
+7% +$948K 1.19% 32
2024
Q3 		$16.8M Sell
15,995
-46
-0.3% -$51.2K 1.64% 30
2024
Q2 		$16.9M Buy
16,041
+134
+0.8% +$130K 1.71% 27
2024
Q1 		$15.3M Sell
15,907
-147
-0.9% -$140K 1.55% 31
2023
Q4 		$14.1M Sell
16,054
-73
-0.5% -$60.1K 1.52% 29
2023
Q3 		$13.3M Sell
16,127
-80
-0.5% -$62.9K 1.61% 29
2023
Q2 		$11.6M Sell
16,207
-706
-4% -$544K 1.35% 30
2023
Q1 		$13.9M Sell
16,913
-20,226
-54% -$15.3M 1.7% 26
2022
Q4 		$26.8M Sell
37,139
-851
-2% -$628K 3.4% 8
2022
Q3 		$26.2M Sell
37,990
-5,850
-13% -$3.68M 3.5% 7
2022
Q2 		$25.9M Sell
43,840
-2,492
-5% -$1.62M 3.2% 10
2022
Q1 		$32.4M Sell
46,332
-450
-1% -$285K 3.26% 10
2021
Q4 		$29.5M Buy
46,782
+290
+0.6% +$178K 2.79% 13
2021
Q3 		$28.1M Sell
46,492
-95
-0.2% -$59K 2.93% 12
2021
Q2 		$26M Buy
46,587
+425
+0.9% +$215K 2.72% 13
2021
Q1 		$21.8M Buy
+46,162
New +$22.5M 2.52% 16

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Taurus Asset Management's REGN Position: Q1 2025 in Review

Taurus Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q1 2025, selling an estimated $285K and leaving 16,711 shares worth $10.6M. The position accounts for 1.07% of the portfolio, ranked #35.

Taurus Asset Management first reported a position in REGN in Q1 2021 and has held it in 17 quarters since. The position peaked at $32.4M in Q1 2022. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Taurus Asset Management held 16,711 shares of Regeneron Pharmaceuticals worth $10.6M as of Q1 2025.
  • Taurus Asset Management sold 414 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $285K.
  • Regeneron Pharmaceuticals made up 1.07% of Taurus Asset Management's portfolio in Q1 2025, its #35 holding.
  • Taurus Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Taurus Asset Management's Regeneron Pharmaceuticals position peaked at $32.4M in Q1 2022.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Taurus Asset Management's 13F filing for Q1 2025, filed 13 May 2025.